ALF 5755

Drug Profile

ALF 5755

Alternative Names: ALF-5755; Recombinant hepatocarcinoma-intestine-pancreas pancreatitis-associated protein; Recombinant HIP/PAP; rhHIP/PAP

Latest Information Update: 09 Feb 2016

Price : $50

At a glance

  • Originator INSERM
  • Developer Alfact Innovation
  • Class Growth factors; Lectins; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Antioxidants; Growth stimulants; Pancreatitis-associated protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alcoholic hepatitis; Hepatitis; Liver cirrhosis; Liver disorders; Liver failure; Neurological disorders

Most Recent Events

  • 09 Feb 2016 No development reported - Phase-I for Alcoholic hepatitis (In volunteers) in France (IV)
  • 09 Feb 2016 No development reported - Phase-I for Cirrhosis (In volunteers) in France (IV)
  • 09 Feb 2016 No development reported - Phase-I for Liver disorders (Prevention, In volunteers) in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top